A post in NPR’s Shots blog reports that Avalanche Biotechnologies and the University of Washington have reached a licensing agreement to develop the first treatment for color blindness. Usually a genetic disorder, the condition affects more than 10 million Americans and can be disabling, preventing people from pursuing certain careers where color plays a big role. Researchers successfully used gene therapy to cure the condition in squirrel monkeys, but it involved surgically delivering new genes to cells in the retina. Now, researchers have found that a harmless injection into the vitreous to deliver the genes may do the trick. The human eye is known to be a safe place to use gene therapy, and experimental treatment for humans should be possible within the next couple of years.